Blood cholesterol LDL and non-HDL treatment goals: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Adding CME Category::Cardiology) |
No edit summary |
||
| Line 7: | Line 7: | ||
primary prevention]] or [[ACC AHA guideline on the treatment of blood cholesterol secondary prevention|secondary prevention]] of atherosclerotic cardiovascular disease (ASCVD) given the lack of evidence on titration of cholesterol-lowering therapy to specific goals. | primary prevention]] or [[ACC AHA guideline on the treatment of blood cholesterol secondary prevention|secondary prevention]] of atherosclerotic cardiovascular disease (ASCVD) given the lack of evidence on titration of cholesterol-lowering therapy to specific goals. | ||
==LDL and | ==2013 ACC AHA guideline on the treatment of blood cholesterol LDL and non-HDL treatment goals== | ||
There are few trials that were designed to define the optimal goals for LDL-C or non-HDL-C by titrating cholesterol-lowering therapy. In AIM-HIGH, the additional reduction in non-HDL–C levels with niacin therapy did not further reduce ASCVD risk in individuals treated to LDL–C levels of 40 to 80 mg/dL.<ref name="Boden-2011">{{Cite journal | last1 = Boden | first1 = WE. | last2 = Probstfield | first2 = JL. | last3 = Anderson | first3 = T. | last4 = Chaitman | first4 = BR. | last5 = Desvignes-Nickens | first5 = P. | last6 = Koprowicz | first6 = K. | last7 = McBride | first7 = R. | last8 = Teo | first8 = K. | last9 = Weintraub | first9 = W. | title = Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. | journal = N Engl J Med | volume = 365 | issue = 24 | pages = 2255-67 | month = Dec | year = 2011 | doi = 10.1056/NEJMoa1107579 | PMID = 22085343 }</ref> Therefore, no recommendations are made for or against specific LDL–C or non-HDL–C goals for the primary or secondary prevention of ASCVD due to the lack of evidence on titration of drug therapy to specific goals. | There are few trials that were designed to define the optimal goals for LDL-C or non-HDL-C by titrating cholesterol-lowering therapy. In AIM-HIGH, the additional reduction in non-HDL–C levels with niacin therapy did not further reduce ASCVD risk in individuals treated to LDL–C levels of 40 to 80 mg/dL.<ref name="Boden-2011">{{Cite journal | last1 = Boden | first1 = WE. | last2 = Probstfield | first2 = JL. | last3 = Anderson | first3 = T. | last4 = Chaitman | first4 = BR. | last5 = Desvignes-Nickens | first5 = P. | last6 = Koprowicz | first6 = K. | last7 = McBride | first7 = R. | last8 = Teo | first8 = K. | last9 = Weintraub | first9 = W. | title = Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. | journal = N Engl J Med | volume = 365 | issue = 24 | pages = 2255-67 | month = Dec | year = 2011 | doi = 10.1056/NEJMoa1107579 | PMID = 22085343 }</ref> Therefore, no recommendations are made for or against specific LDL–C or non-HDL–C goals for the primary or secondary prevention of ASCVD due to the lack of evidence on titration of drug therapy to specific goals. | ||
Revision as of 18:14, 28 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
No recommendations are made for or against specific LDL–C or non-HDL–C goals for the primary prevention or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) given the lack of evidence on titration of cholesterol-lowering therapy to specific goals.
2013 ACC AHA guideline on the treatment of blood cholesterol LDL and non-HDL treatment goals
There are few trials that were designed to define the optimal goals for LDL-C or non-HDL-C by titrating cholesterol-lowering therapy. In AIM-HIGH, the additional reduction in non-HDL–C levels with niacin therapy did not further reduce ASCVD risk in individuals treated to LDL–C levels of 40 to 80 mg/dL.[1] Therefore, no recommendations are made for or against specific LDL–C or non-HDL–C goals for the primary or secondary prevention of ASCVD due to the lack of evidence on titration of drug therapy to specific goals.
References
- ↑ {{Cite journal | last1 = Boden | first1 = WE. | last2 = Probstfield | first2 = JL. | last3 = Anderson | first3 = T. | last4 = Chaitman | first4 = BR. | last5 = Desvignes-Nickens | first5 = P. | last6 = Koprowicz | first6 = K. | last7 = McBride | first7 = R. | last8 = Teo | first8 = K. | last9 = Weintraub | first9 = W. | title = Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. | journal = N Engl J Med | volume = 365 | issue = 24 | pages = 2255-67 | month = Dec | year = 2011 | doi = 10.1056/NEJMoa1107579 | PMID = 22085343 }